Trial Profile
Double-blind study of the effect of selective serotonin reuptake inhabitor fluvoxamine on cognitive deficits in schizophrenia.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Jul 2020
Price :
$35
*
At a glance
- Drugs Fluvoxamine (Primary)
- Indications Schizophrenia
- Focus Pharmacodynamics
- 30 Jun 2020 Results of meta analysis examining the therapeutic effects and tolerability of adjunctive fluvoxamine versus placebo for schizophrenia published in the Journal of Clinical Psychopharmacology
- 08 Jun 2011 Status changed from active, no longer recruiting to completed.
- 04 Feb 2010 New trial record